Overexpression of Eag1 potassium channels in clinical tumours.
Hemmerlein B,
Weseloh RM,
Mello de Queiroz F,
Knötgen H,
Sánchez A,
Rubio ME,
Martin S,
Schliephacke T,
Jenke M,
Heinz-Joachim-Radzun,
Stühmer W,
Pardo LA.
Department of Pathology, Georg-August University, Göttingen, Germany. hemmer@med.uni-goettingen.de
BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.
PMID: 17022810 [PubMed - indexed for MEDLINE]
PMCID: PMC1621079